Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco Ltd. (IVZ) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

Invesco Ltd.Trade
DENTSPLY SIRONA IncTrade

Price performance (Past 24H)

Key statistics

Invesco Ltd. vs DENTSPLY SIRONA Inc — how do they compare? Invesco Ltd. trades at $29.69 (market cap $13.28B), while DENTSPLY SIRONA Inc trades at $8.74 (market cap $1.73B). The key difference: Invesco Ltd. is far larger — about 7.7× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals — on Pluang, investors hold Invesco Ltd. for 77 Days and DENTSPLY SIRONA Inc for 72 Days on average.

IVZXRAY
Market Cap
$13.28B$1.73B
Volume
3,698,0336,198,582
Sector
FinancialsHealth
52-Week High
$33.31$14.68
52-Week Low
$22.44$8.52
Typical Hold Time
77 Days72 Days
Enterprise Value
$23.45B$3.80B
Dividend Yield
2.86%5.04%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco Ltd.

Invesco (IVZ) trades at $29.66, down 2.75% today, with mixed technical signals showing bearish momentum but oversold conditions on some indicators. Fundamentally, the company reported negative net income of -$282 million in 2025 despite $6.38 billion revenue, though operating cash flow remains strong at $1.53 billion. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results expected October 27.

The outlook remains cautious with analyst consensus at Buy (43%) and Hold (57%), targeting $33.71. Key risks include profitability challenges and market volatility, while opportunities lie in AUM growth and dividend yield. The stock trades near the lower end of analyst targets, suggesting limited downside but requiring improved earnings for sustained recovery.

DENTSPLY SIRONA Inc

DENTSPLY SIRONA (XRAY) trades at $8.54, near its 52-week low, with bearish technical indicators and mixed fundamentals. The company reported Q2 2026 EPS of $0.52 beating expectations but revenue declined 4.1% year-over-year. Net income remains negative at -$598 million for 2025, though margins show slight improvement. Analyst consensus is mixed with 37.5% buy ratings but a $13.40 price target suggesting 57% upside potential from current levels.

The stock presents a high-risk turnaround opportunity with significant upside if management's restructuring efforts succeed, but faces headwinds from declining sales, margin pressure, and competitive challenges in dental markets. Institutional ownership changes and ongoing transformation investments create both uncertainty and potential for recovery.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ →

About DENTSPLY SIRONA Inc

Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters

Read more on XRAY →